Although nephrotoxicity has frequently limited conventional treatment with cisplatin to doses of 100–120 mg/m2 per cycle, vigorous chloruresis can permit the administration of high-dose cisplatin (200 mg/m2 per cycle) with minimal nephrotoxicity. Systemic toxicities are worsened, but therapeutic response seems to be enhanced. The pharmacokinetics of cisplatin in plasma and urine were examined to assess the causes of these effects. Plasma disappearance of ultrafiltrable platinum was well-described by a single exponential for each patient. The mean t1/2 was 50% longer for patients receiving high-dose cisplatin than for patients receiving conventional doses. The total systemic exposure was three times greater in the high-dose group, which tends to explain the systemic toxicity and improved tumor efficacy, but not the lack of nephrotoxicity. It is suggested that the kidneys of patients in the high-dose group were relatively protected by dilution of active Pt species in the urine in the tubule lumen as well as by high chloride ion concentrations in the urine.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Belt RJ, Himmelstein KJ, Patton TF, Bannister SJ, Sternson LA, Repta AJ (1979) Pharmacokinetics of non-protein-bound platinum species following administration ofcis-dichlorodiammineplatinum (II). Cancer Treat Rep 63:1515–1521
Chary KK, Higby DJ, Henderson ES, Swinerton KD (1977) Phase I study of high-dosecis-dichlorodiammineplatinum (II) with forced diuresis. Cancer Treat Rep 61:367–370
Einhorn LH, Donahue J (1977)cis-Diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87:293–298
Gormley PE, Bull JM, LeRoy AF, Cysyk R (1979) Kinetics ofcis-dichlorodiammineplatinum. Clin Pharmacol Ther 25:351–357
Greene RF, Chatterji DC, Hiranaka PK, Galleli JF (1979) Stability of cisplatin in aqueous solution. Am J Hosp Pharm 36:38–43
Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ (1981) Clinical kinetics of intact cisplatin and some related species. Clin Pharmacol Ther 29:658–664
Hrushesky WJM, Borch R, Levi F (1982) Circadian time dependence of cisplatin urinary kinetics. Clin Pharmacol Ther 32:330–339
Jacobs C, Kalman SM, Tretton M, Weiner MW (1980) Renal handling ofcis-diamminedichloroplatinum (II). Cancer Treat Rep 64:1223–1226
LeRoy AF, Wehling ML, Sponseller AL, Friauf WS, Solomon SE, Dedrick RL, Litterst CL, Gram TE, Guarino AM, Becker DA (1977) Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18:184–191
Madias NE, Harrington JT (1978) Platinum nephrotoxicity. Am J Med 65:307–314
Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y, Young RC (1984) High-dose cisplatin in hypertonic saline. Ann Intern Med 100:19–24
Schmoll H-J, Weiss J, Arnold H, Dolken G, Mayr T, Hoffman L, Douwes FW, Hossfeld DK (1983) Platinum ultra high dose/etoposide/bleomycin in testicular carcinoma: toxicity and activity. (Abstract) J Invest New Drugs 2:124
Weiner MW, Jacobs C (1983) Mechanism of cisplatin nephrotoxicity. Fed Proc 42:2974–2978
Wittes RE, Cvitkovic E, Shah J, Gerold FP, Strong EW (1977)cis-Dichlorodiammineplatinum (II) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep 61:359–366
Young RC, Von Hoff DD, Gormley P, Makuch R, Cassidy J, Howser D, Bull JM (1979)cis-Diamminedichloroplatinum (II) for the treatment of advanced ovarian cancer. Cancer Treat Rep 63:1539–1544
About this article
Cite this article
Corden, B.J., Fine, R.L., Ozols, R.F. et al. Clinical pharmacology of high-dose cisplatin. Cancer Chemother. Pharmacol. 14, 38–41 (1985). https://doi.org/10.1007/BF00552723
- Clinical Pharmacology
- Conventional Treatment
- Therapeutic Response
- Systemic Exposure